

CRO Communiqué
Keeping you informed about CRO progress
September 2013

Top Enrolling Physicians for August 2013

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Abdalla (Cox)	1	1	0	1
Dr. Carlson (Mercy Spfld)	8	2.9	2.5	5.4
Dr. Coplin (Mercy St. Louis)	3	1	2	3
Dr. Creach (Mercy Spfld)	2	1	0.5	1.5
Dr. Cunningham (Cox)	2	1	1	2
Dr. Ellis (Cox)	1	1	0	1
Dr. Finnie (Mercy St. Louis)	2	0	1	1
Dr. Hu (Mercy St. Louis)	2	0	1	1
Dr. Luedke(Mercy St. Louis)	1	1	0	1
Dr. Miller (Freeman)	1	1	0	1
Dr. Oza (Good Samaritan)	4	0	2	2
Dr. Raju (Mercy Spfld)	1	0	0.5	0.5
Dr. Rodgers (Mercy St. Louis)	1	0	0.5	0.5
Dr. Tummala(Mercy Spfld)	1	0	0.5	0.5
Total	30	9.9	11.5	21.2

Our accruals are much better this month. YEA! Thirty trial registrations were made by fourteen investigators. CRO earned 9.9 treatment and 11.5 cancer control credits totaling 21.8 total credits.

Shorter Consent Forms for NCI

The NCI's Consent Form Template for adult trials has been revised to result in shorter, more concise, consent forms for NCI-sponsored trials. The major changes that have resulted from this review include: a "lay" title in addition to the official study title, brief description of "usual care" to place research in context, text examples of various trial types and phases, section limits, risks described from a study participant's perspective and potential side effects listed using a table format in the "Risks" section. The May 12, 2013 version of the NCI Consent Form Template is posted on the NCI's website at <http://cancer.gov/clinicaltrials/understanding/simplification-of-informed-consent-docs/page3>. DCP will begin using the new version of the Consent Form Template (dated May 12, 2013) for all cancer control and prevention trials effective September 1, 2013.

NCORP Grant

We continue to work on what we anticipate will be required in the NCORP grant request and await the official grant release. NCI is sponsoring a PI and Administrators Conference at NIH on September 20th. Marilyn Bauer will be attending. Hopefully, we will hear final details at this meeting.

Terry Fox Run

Terry Martin, a nurse anesthetist in Bolivar at CMH is starting a local Terry Fox Run to benefit CRO. Terry (Martin) has created a website for the run; it is <http://terryfoxrunmissouri.org/index.html>. You can view a YouTube video to hear about Terry Fox and his run to raise money for cancer research. Here is the link http://www.youtube.com/watch?v=xjgTICTluPA&feature=player_embedded I highly recommend you have a box of Kleenex with you. Some may need to send the link to your home email or phone as YouTube videos are blocked at Cox.

Terry Martin was inspired by Terry Fox while a teenager as he struggled with the challenges of spinal bifida. The run is scheduled for 9/28/2013 at SBU in Bolivar. KY3 will be there to capture the story including that all proceeds will benefit CRO. Participants do not have to run a 5K, there will be short walks just around the football field for those too young, too old or not able to run a 5K for whatever reason. Participants in the Terry Fox Run Bolivar are asked only to give a donation to help fund cancer research. This contribution can be given the morning of the run, dropped off at

CRO or mailed. It would be great if CRO investigators and staff attend. Terry Martin's plan is to make this an annual event to benefit CRO.

CRO Affiliate Representatives to Join CRO Executive Board

The following physicians will be representing their site on the CRO Executive Board: Dr. John Vu from Freeman, Dr. David Croy from Mercy Joplin, Dr. Leo Shunyakov from Central Care PA, Dr. Yaqoob Ali from Phelps County, Dr. Bethany Sleckman from Mercy St. Louis, and Dr Yagnesh Oza from Good Samaritan. Special thanks to these individuals for adding another important meeting to their calendar. Our next Executive Board will be Wednesday, September 11th at 12pm.

New Studies Approved in August, 2013

Opened at Cox and Mercy Springfield

GOG 0237 Comparative Analysis of CA-IX, p16, Proliferative Markers and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC)

RTOG 1201 A Phase II Randomized Trial of High Versus Standard Intensity Local or Systemic Therapy for Unresectable Pancreatic Cancer

RTOG 1216 Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Studies Permanently Closed to Enrollment at Cox & Mercy in August 2013

CTSU ECOG E3108 A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen

GOG 0262 A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

RTOG 0929 A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma

RTOG 1016 Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

GOG 0127W A Phase II Evaluation of ABT-888 (IND #77840), Topotecan and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix

SWOG S1014 Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II.